Strides Pharma Science Ltd
NSE:STAR
Cash Flow Statement
Cash Flow Statement
Strides Pharma Science Ltd
| Mar-2020 | Sep-2020 | Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||
| Net Income |
547
|
592
|
2 754
|
(3 169)
|
(6 525)
|
(4 351)
|
(2 862)
|
(2 413)
|
(1 169)
|
2 397
|
4 869
|
5 620
|
|
| Depreciation & Amortization |
1 878
|
1 907
|
2 063
|
2 158
|
2 330
|
2 437
|
2 433
|
2 408
|
2 207
|
1 960
|
1 923
|
1 958
|
|
| Stock-Based Compensation |
18
|
0
|
68
|
0
|
0
|
0
|
13
|
0
|
16
|
0
|
16
|
0
|
|
| Other Non-Cash Items |
3 335
|
3 392
|
1 710
|
3 722
|
3 493
|
2 864
|
4 575
|
6 364
|
6 518
|
2 921
|
1 019
|
1 080
|
|
| Cash Taxes Paid |
450
|
439
|
(1 568)
|
(1 841)
|
(23)
|
(140)
|
(876)
|
(1 017)
|
(242)
|
(887)
|
(670)
|
287
|
|
| Cash Interest Paid |
1 708
|
1 325
|
1 394
|
1 484
|
1 538
|
1 845
|
2 242
|
2 556
|
2 922
|
2 988
|
2 405
|
1 896
|
|
| Change in Working Capital |
(3 712)
|
(3 193)
|
(1 713)
|
(1 140)
|
(1 876)
|
(2 097)
|
(3 705)
|
(2 457)
|
(546)
|
(157)
|
(967)
|
(1 033)
|
|
| Cash from Operating Activities |
2 048
N/A
|
2 699
+32%
|
4 814
+78%
|
1 572
-67%
|
(2 578)
N/A
|
(1 148)
+55%
|
441
N/A
|
3 903
+786%
|
7 009
+80%
|
7 787
+11%
|
6 844
-12%
|
6 960
+2%
|
|
| Investing Cash Flow | |||||||||||||
| Capital Expenditures |
(1 500)
|
(1 730)
|
(2 975)
|
(2 760)
|
(1 434)
|
(957)
|
(949)
|
(861)
|
(1 182)
|
(1 732)
|
(2 425)
|
(2 971)
|
|
| Other Items |
14 562
|
(1 623)
|
(2 233)
|
1 342
|
247
|
(2 046)
|
3 974
|
2 620
|
(321)
|
2 053
|
1 528
|
892
|
|
| Cash from Investing Activities |
13 062
N/A
|
(3 352)
N/A
|
(5 208)
-55%
|
(1 418)
+73%
|
(1 187)
+16%
|
(3 003)
-153%
|
3 025
N/A
|
1 759
-42%
|
(1 503)
N/A
|
321
N/A
|
(897)
N/A
|
(2 079)
-132%
|
|
| Financing Cash Flow | |||||||||||||
| Net Issuance of Common Stock |
5
|
24
|
37
|
45
|
36
|
392
|
385
|
8
|
527
|
531
|
61
|
52
|
|
| Net Issuance of Debt |
(13 843)
|
1 470
|
1 378
|
3 904
|
5 939
|
3 029
|
(282)
|
(3 101)
|
(4 403)
|
(5 108)
|
(3 852)
|
(2 731)
|
|
| Cash Paid for Dividends |
(1 539)
|
(179)
|
(179)
|
(224)
|
(224)
|
0
|
0
|
(123)
|
(135)
|
(242)
|
(230)
|
(369)
|
|
| Other |
(1 718)
|
(1 325)
|
(1 394)
|
(1 484)
|
(1 538)
|
(1 845)
|
(2 242)
|
(2 556)
|
(2 922)
|
(2 988)
|
(2 405)
|
(1 896)
|
|
| Cash from Financing Activities |
(17 095)
N/A
|
(10)
+100%
|
(158)
-1 512%
|
2 242
N/A
|
4 213
+88%
|
1 576
-63%
|
(2 139)
N/A
|
(5 772)
-170%
|
(6 933)
-20%
|
(7 807)
-13%
|
(6 426)
+18%
|
(4 943)
+23%
|
|
| Change in Cash | |||||||||||||
| Effect of Foreign Exchange Rates |
149
|
178
|
(12)
|
(2)
|
1
|
2
|
1
|
(10)
|
2
|
12
|
(5)
|
(8)
|
|
| Net Change in Cash |
(1 837)
N/A
|
(485)
+74%
|
(564)
-16%
|
2 393
N/A
|
449
-81%
|
(2 573)
N/A
|
1 328
N/A
|
(120)
N/A
|
(1 425)
-1 087%
|
314
N/A
|
(485)
N/A
|
(70)
+85%
|
|
| Free Cash Flow | |||||||||||||
| Free Cash Flow |
548
N/A
|
970
+77%
|
1 840
+90%
|
(1 188)
N/A
|
(4 012)
-238%
|
(2 104)
+48%
|
(509)
+76%
|
3 043
N/A
|
5 828
+92%
|
6 055
+4%
|
4 419
-27%
|
3 989
-10%
|
|